Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...
Zacks Investment Research on MSN2h
FDA Grants Accelerated Approval to NVS Kidney Disease DrugNovartis NVS obtains FDA approval of atrasentan, a potent and selective endothelin A (ETA) receptor antagonist, for the ...
In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial ...
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...
Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...
Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...
CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.
Safeguards Of Dapagliflozin's Half Billion USD Sales In China: Astrazeneca. Legal News and Analysis - China - Conventus Law ...
The Nation Newspaper Internal Medicine Specialist warns of rare diabetes complication linked to SGLT2 inhibitors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback